CYP19A1 and pulmonary arterial hypertension: Similar to the increased aromatization of androgens in postmenopausal women and men with PAH [46,47], in patients with portopulmonary PAH, irrespective of sex, elevated aromatase activity and plasma E2 levels are associated with increased risk of PAH [58].